Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes
Abstract
:1. Introduction of Mitochondria
1.1. Structure of Mitochondria
1.2. Mitochondria, the Powerhouse of the Cell
1.3. Mitochondrial Genetics
2. Clinical Manifestations of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome
3. Genetics and Pathogenesis of MELAS Syndrome
3.1. Genetics of MELAS Syndrome
3.2. Pathogenesis of Stroke-Like Episodes of MELAS Syndrome
3.2.1. Insufficient Energy
3.2.2. Angiopathy
3.2.3. NO Production Deficiency
4. Diagnosis
4.1. Treatment
4.1.1. Vitamin B1
4.1.2. Vitamin B2
4.1.3. Vitamin B3
4.1.4. Vitamin B7
4.1.5. Vitamin B9
4.1.6. Vitamin B12
4.1.7. Vitamin E
4.1.8. Coenzyme Q10
4.1.9. N-acetylcysteine (NAC)
4.1.10. Vitamin C (Ascorbic Acid)
4.1.11. Levocarnitine (L-carnitine)
4.1.12. Creatine
4.1.13. Levoarginine (L-arginine)
4.1.14. Aerobic Training
4.1.15. Mitochondrial Replacement Therapy (MRT)
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Robin, E.D.; Wong, R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J. Cell. Physiol. 1988, 136, 507–513. [Google Scholar] [CrossRef]
- Miyazono, Y.; Hirashima, S.; Ishihara, N.; Kusukawa, J.; Nakamura, K.I.; Ohta, K. Uncoupled mitochondria quickly shorten along their long axis to form indented spheroids, instead of rings, in a fission-independent manner. Sci. Rep. 2018, 8, 350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zick, M.; Rabl, R.; Reichert, A.S. Cristae formation-linking ultrastructure and function of mitochondria. Biochim. Biophys. Acta 2009, 1793, 5–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rafelski, S.M. Mitochondrial network morphology: Building an integrative, geometrical view. BMC Biol. 2013, 11, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vogel, F.; Bornhovd, C.; Neupert, W.; Reichert, A.S. Dynamic subcompartmentalization of the mitochondrial inner membrane. J. Cell Biol. 2006, 175, 237–247. [Google Scholar] [CrossRef]
- Bowsher, C.G.; Tobin, A.K. Compartmentation of metabolism within mitochondria and plastids. J. Exp. Bot. 2001, 52, 513–527. [Google Scholar] [CrossRef]
- Vandecasteele, G.; Szabadkai, G.; Rizzuto, R. Mitochondrial calcium homeostasis: Mechanisms and molecules. IUBMB Life 2001, 52, 213–219. [Google Scholar] [CrossRef]
- Youle, R.J.; Karbowski, M. Mitochondrial fission in apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6, 657–663. [Google Scholar] [CrossRef]
- Bratic, I.; Trifunovic, A. Mitochondrial energy metabolism and ageing. Biochim. Biophys. Acta 2010, 1797, 961–967. [Google Scholar] [CrossRef] [Green Version]
- van der Bliek, A.M.; Sedensky, M.M.; Morgan, P.G. Cell biology of the mitochondrion. Genetics 2017, 207, 843–871. [Google Scholar] [CrossRef] [Green Version]
- Akram, M. Citric acid cycle and role of its intermediates in metabolism. Cell Biochem. Biophys. 2014, 68, 475–478. [Google Scholar] [CrossRef]
- Chinnery, P.F.; Hudson, G. Mitochondrial genetics. Br. Med. Bull. 2013, 106, 135–159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Debray, F.G.; Lambert, M.; Mitchell, G.A. Disorders of mitochondrial function. Curr. Opin. Pediatr. 2008, 20, 471–482. [Google Scholar] [CrossRef]
- Jang, Y.H.; Ahn, S.R.; Shim, J.Y.; Lim, K.I. Engineering genetic systems for treating mitochondrial diseases. Pharmaceutics 2021, 13, 810. [Google Scholar] [CrossRef] [PubMed]
- Alston, C.L.; Rocha, M.C.; Lax, N.Z.; Turnbull, D.M.; Taylor, R.W. The genetics and pathology of mitochondrial disease. J. Pathol. 2017, 241, 236–250. [Google Scholar] [CrossRef] [PubMed]
- Tuppen, H.A.; Blakely, E.L.; Turnbull, D.M.; Taylor, R.W. Mitochondrial DNA mutations and human disease. Biochim. Biophys. Acta 2010, 1797, 113–128. [Google Scholar] [CrossRef] [Green Version]
- Scholle, L.M.; Zierz, S.; Mawrin, C.; Wickenhauser, C.; Urban, D.L. Heteroplasmy and copy number in the common m.3243a>g mutation-a post-mortem genotype-phenotype analysis. Genes 2020, 11, 212. [Google Scholar] [CrossRef] [Green Version]
- DiMauro, S. Mitochondrial DNA mutation load: Chance or destiny? JAMA Neurol. 2013, 70, 1484–1485. [Google Scholar] [CrossRef] [Green Version]
- Chinnery, P.F.; Turnbull, D.M. Epidemiology and treatment of mitochondrial disorders. Am. J. Med. Genet. 2001, 106, 94–101. [Google Scholar] [CrossRef]
- Yatsuga, S.; Povalko, N.; Nishioka, J.; Katayama, K.; Kakimoto, N.; Matsuishi, T.; Kakuma, T.; Koga, Y.; Taro Matsuoka for MELAS Study Group in Japan. Melas: A nationwide prospective cohort study of 96 patients in japan. Biochim. Biophys. Acta 2012, 1820, 619–624. [Google Scholar] [CrossRef]
- Chinnery, P.F.; Johnson, M.A.; Wardell, T.M.; Singh-Kler, R.; Hayes, C.; Brown, D.T.; Taylor, R.W.; Bindoff, L.A.; Turnbull, D.M. The epidemiology of pathogenic mitochondrial DNA mutations. Ann. Neurol. 2000, 48, 188–193. [Google Scholar] [CrossRef]
- Darin, N.; Oldfors, A.; Moslemi, A.R.; Holme, E.; Tulinius, M. The incidence of mitochondrial encephalomyopathies in childhood: Clinical features and morphological, biochemical, and DNA abnormalities. Ann. Neurol. 2001, 49, 377–383. [Google Scholar] [CrossRef]
- Uusimaa, J.; Moilanen, J.S.; Vainionpaa, L.; Tapanainen, P.; Lindholm, P.; Nuutinen, M.; Lopponen, T.; Maki-Torkko, E.; Rantala, H.; Majamaa, K. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243a>g mutation in children. Ann. Neurol. 2007, 62, 278–287. [Google Scholar] [CrossRef] [PubMed]
- Manwaring, N.; Jones, M.M.; Wang, J.J.; Rochtchina, E.; Howard, C.; Mitchell, P.; Sue, C.M. Population prevalence of the melas a3243g mutation. Mitochondrion 2007, 7, 230–233. [Google Scholar] [CrossRef]
- Hirano, M.; Pavlakis, S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (melas): Current concepts. J. Child. Neurol. 1994, 9, 4–13. [Google Scholar] [CrossRef] [PubMed]
- Sproule, D.M.; Kaufmann, P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: Basic concepts, clinical phenotype, and therapeutic management of melas syndrome. Ann. N. Y. Acad. Sci. 2008, 1142, 133–158. [Google Scholar] [CrossRef]
- DiMauro, S. Mitochondrial encephalomyopathies--fifty years on: The robert wartenberg lecture. Neurology 2013, 81, 281–291. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Kumar Sharma, L.; Li, Y.; Hu, P.; Idowu, A.; Liu, D.; Lu, J.; Bai, Y. Comparative bioenergetic study of neuronal and muscle mitochondria during aging. Free Radic. Biol. Med. 2013, 63, 30–40. [Google Scholar] [CrossRef] [Green Version]
- Finsterer, J.; Zarrouk-Mahjoub, S. Focal and generalized seizures may occur in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (melas) patients. J. Child. Neurol. 2015, 30, 1553–1554. [Google Scholar] [CrossRef]
- Ng, Y.S.; Bindoff, L.A.; Gorman, G.S.; Horvath, R.; Klopstock, T.; Mancuso, M.; Martikainen, M.H.; McFarland, R.; Nesbitt, V.; Pitceathly, R.D.S.; et al. Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res. 2019, 4, 201. [Google Scholar] [CrossRef] [Green Version]
- Lax, N.Z.; Grady, J.; Laude, A.; Chan, F.; Hepplewhite, P.D.; Gorman, G.; Whittaker, R.G.; Ng, Y.; Cunningham, M.O.; Turnbull, D.M. Extensive respiratory chain defects in inhibitory interneurones in patients with mitochondrial disease. Neuropathol. Appl. Neurobiol. 2016, 42, 180–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaufmann, P.; Engelstad, K.; Wei, Y.; Kulikova, R.; Oskoui, M.; Sproule, D.M.; Battista, V.; Koenigsberger, D.Y.; Pascual, J.M.; Shanske, S.; et al. Natural history of melas associated with mitochondrial DNA m.3243a>g genotype. Neurology 2011, 77, 1965–1971. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karppa, M.; Syrjala, P.; Tolonen, U.; Majamaa, K. Peripheral neuropathy in patients with the 3243a>g mutation in mitochondrial DNA. J. Neurol. 2003, 250, 216–221. [Google Scholar] [PubMed]
- Kaufmann, P.; Pascual, J.M.; Anziska, Y.; Gooch, C.L.; Engelstad, K.; Jhung, S.; DiMauro, S.; De Vivo, D.C. Nerve conduction abnormalities in patients with melas and the a3243g mutation. Arch. Neurol. 2006, 63, 746–748. [Google Scholar] [CrossRef] [Green Version]
- Anglin, R.E.; Garside, S.L.; Tarnopolsky, M.A.; Mazurek, M.F.; Rosebush, P.I. The psychiatric manifestations of mitochondrial disorders: A case and review of the literature. J. Clin. Psychiatry 2012, 73, 506–512. [Google Scholar] [CrossRef]
- Okajima, Y.; Tanabe, Y.; Takayanagi, M.; Aotsuka, H. A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (melas). Heart 1998, 80, 292–295. [Google Scholar] [CrossRef]
- Fujii, A.; Yoneda, M.; Ohtani, M.; Nakagawa, H.; Kumano, T.; Hayashi, K.; Muramatsu, A.; Takabatake, S.; Ibi, T.; Sahashi, K.; et al. Gastric dysmotility associated with accumulation of mitochondrial a3243g mutation in the stomach. Intern. Med. 2004, 43, 1126–1130. [Google Scholar] [CrossRef] [Green Version]
- Koga, Y.; Akita, Y.; Nishioka, J.; Yatsuga, S.; Povalko, N.; Tanabe, Y.; Fujimoto, S.; Matsuishi, T. L-arginine improves the symptoms of strokelike episodes in melas. Neurology 2005, 64, 710–712. [Google Scholar] [CrossRef]
- Maassen, J.A.; LM, T.H.; Van Essen, E.; Heine, R.J.; Nijpels, G.; Jahangir Tafrechi, R.S.; Raap, A.K.; Janssen, G.M.; Lemkes, H.H. Mitochondrial diabetes: Molecular mechanisms and clinical presentation. Diabetes 2004, 53 (Suppl. 1), S103–S109. [Google Scholar] [CrossRef] [Green Version]
- El-Hattab, A.W.; Emrick, L.T.; Hsu, J.W.; Chanprasert, S.; Jahoor, F.; Scaglia, F.; Craigen, W.J. Glucose metabolism derangements in adults with the melas m.3243a>g mutation. Mitochondrion 2014, 18, 63–69. [Google Scholar] [CrossRef] [Green Version]
- Jonk, A.M.; Houben, A.J.; de Jongh, R.T.; Serne, E.H.; Schaper, N.C.; Stehouwer, C.D. Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 2007, 22, 252–260. [Google Scholar] [CrossRef] [PubMed]
- Schaefer, A.M.; Walker, M.; Turnbull, D.M.; Taylor, R.W. Endocrine disorders in mitochondrial disease. Mol. Cell Endocrinol. 2013, 379, 2–11. [Google Scholar] [CrossRef] [PubMed]
- Ge, Y.X.; Shang, B.; Chen, W.Z.; Lu, Y.; Wang, J. Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (melas) syndrome with hypothyroidism and psychiatric disorders. eNeurologicalSci 2017, 6, 16–20. [Google Scholar] [CrossRef]
- Tanaka, K.; Takada, Y.; Matsunaka, T.; Yuyama, S.; Fujino, S.; Maguchi, M.; Yamashita, S.; Yuba, I. Diabetes mellitus, deafness, muscle weakness and hypocalcemia in a patient with an a3243g mutation of the mitochondrial DNA. Intern. Med. 2000, 39, 249–252. [Google Scholar] [CrossRef] [Green Version]
- Topaloglu, H.; Seyrantepe, V.; Kandemir, N.; Akcoren, Z.; Ozguc, M. Mtdna nt3243 mutation, external ophthalmoplegia, and hypogonadism in an adolescent girl. Pediatr. Neurol. 1998, 18, 429–431. [Google Scholar] [CrossRef]
- Hotta, O.; Inoue, C.N.; Miyabayashi, S.; Furuta, T.; Takeuchi, A.; Taguma, Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial trnaleu(uur) gene mutation. Kidney Int. 2001, 59, 1236–1243. [Google Scholar] [CrossRef] [Green Version]
- Finsterer, J. Chronic anemia as a manifestation of melas syndrome. Rev. Investig. Clin. 2011, 63, 100–103. [Google Scholar]
- Naue, J.; Horer, S.; Sanger, T.; Strobl, C.; Hatzer-Grubwieser, P.; Parson, W.; Lutz-Bonengel, S. Evidence for frequent and tissue-specific sequence heteroplasmy in human mitochondrial DNA. Mitochondrion 2015, 20, 82–94. [Google Scholar] [CrossRef]
- Calvo, S.; Jain, M.; Xie, X.; Sheth, S.A.; Chang, B.; Goldberger, O.A.; Spinazzola, A.; Zeviani, M.; Carr, S.A.; Mootha, V.K. Systematic identification of human mitochondrial disease genes through integrative genomics. Nat. Genet. 2006, 38, 576–582. [Google Scholar] [CrossRef]
- Mitomap a Human Mitochondrial Genome Database. Available online: https://www.Mitomap.Org/mitomap (accessed on 1 May 2021).
- Karicheva, O.Z.; Kolesnikova, O.A.; Schirtz, T.; Vysokikh, M.Y.; Mager-Heckel, A.M.; Lombes, A.; Boucheham, A.; Krasheninnikov, I.A.; Martin, R.P.; Entelis, N.; et al. Correction of the consequences of mitochondrial 3243a>g mutation in the mt-tl1 gene causing the melas syndrome by trna import into mitochondria. Nucleic Acids Res. 2011, 39, 8173–8186. [Google Scholar] [CrossRef] [Green Version]
- Nesbitt, V.; Pitceathly, R.D.; Turnbull, D.M.; Taylor, R.W.; Sweeney, M.G.; Mudanohwo, E.E.; Rahman, S.; Hanna, M.G.; McFarland, R. The uk mrc mitochondrial disease patient cohort study: Clinical phenotypes associated with the m.3243a>g mutation--implications for diagnosis and management. J. Neurol. Neurosurg. Psychiatry 2013, 84, 936–938. [Google Scholar] [CrossRef]
- Fabrizi, G.M.; Cardaioli, E.; Grieco, G.S.; Cavallaro, T.; Malandrini, A.; Manneschi, L.; Dotti, M.T.; Federico, A.; Guazzi, G. The a to g transition at nt 3243 of the mitochondrial trnaleu(uur) may cause an merrf syndrome. J. Neurol. Neurosurg. Psychiatry 1996, 61, 47–51. [Google Scholar] [CrossRef] [Green Version]
- Koga, Y.; Akita, Y.; Takane, N.; Sato, Y.; Kato, H. Heterogeneous presentation in a3243g mutation in the mitochondrial trna(leu(uur)) gene. Arch. Dis. Child. 2000, 82, 407–411. [Google Scholar] [CrossRef]
- Vodopivec, I.; Cho, T.A.; Rizzo, J.F., 3rd; Frosch, M.P.; Sims, K.B. Mitochondrial encephalopathy and optic neuropathy due to m.10158 mt-nd3 complex i mutation presenting in an adult patient: Case report and review of the literature. Neurologist 2016, 21, 61–65. [Google Scholar] [CrossRef]
- Shanske, S.; Coku, J.; Lu, J.; Ganesh, J.; Krishna, S.; Tanji, K.; Bonilla, E.; Naini, A.B.; Hirano, M.; DiMauro, S. The g13513a mutation in the nd5 gene of mitochondrial DNA as a common cause of melas or leigh syndrome: Evidence from 12 cases. Arch. Neurol. 2008, 65, 368–372. [Google Scholar] [CrossRef] [Green Version]
- Wang, S.; Song, T.; Wang, S. Mitochondrial DNA 10158t>c mutation in a patient with mitochondrial encephalomyopathy with lactic acidosis, and stroke-like episodes syndrome: A case-report and literature review (care-complaint). Medicine 2020, 99, e20310. [Google Scholar] [CrossRef]
- Deschauer, M.; Tennant, S.; Rokicka, A.; He, L.; Kraya, T.; Turnbull, D.M.; Zierz, S.; Taylor, R.W. Melas associated with mutations in the polg1 gene. Neurology 2007, 68, 1741–1742. [Google Scholar] [CrossRef]
- Wilichowski, E.; Korenke, G.C.; Ruitenbeek, W.; De Meirleir, L.; Hagendorff, A.; Janssen, A.J.; Lissens, W.; Hanefeld, F. Pyruvate dehydrogenase complex deficiency and altered respiratory chain function in a patient with kearns-sayre/melas overlap syndrome and a3243g mtdna mutation. J. Neurol. Sci. 1998, 157, 206–213. [Google Scholar] [CrossRef]
- El-Hattab, A.W.; Emrick, L.T.; Chanprasert, S.; Craigen, W.J.; Scaglia, F. Mitochondria: Role of citrulline and arginine supplementation in melas syndrome. Int. J. Biochem. Cell Biol. 2014, 48, 85–91. [Google Scholar] [CrossRef] [PubMed]
- El-Hattab, A.W.; Hsu, J.W.; Emrick, L.T.; Wong, L.J.; Craigen, W.J.; Jahoor, F.; Scaglia, F. Restoration of impaired nitric oxide production in melas syndrome with citrulline and arginine supplementation. Mol. Genet. Metab. 2012, 105, 607–614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koga, Y.; Povalko, N.; Nishioka, J.; Katayama, K.; Kakimoto, N.; Matsuishi, T. Melas and l-arginine therapy: Pathophysiology of stroke-like episodes. Ann. N. Y. Acad. Sci. 2010, 1201, 104–110. [Google Scholar] [CrossRef]
- El-Hattab, A.W.; Adesina, A.M.; Jones, J.; Scaglia, F. Melas syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol. Genet. Metab. 2015, 116, 4–12. [Google Scholar] [CrossRef]
- Bindu, P.S.; Sonam, K.; Govindaraj, P.; Govindaraju, C.; Chiplunkar, S.; Nagappa, M.; Kumar, R.; Vekhande, C.C.; Arvinda, H.R.; Gayathri, N.; et al. Outcome of epilepsy in patients with mitochondrial disorders: Phenotype genotype and magnetic resonance imaging correlations. Clin. Neurol. Neurosurg. 2018, 164, 182–189. [Google Scholar] [CrossRef] [PubMed]
- Weiduschat, N.; Kaufmann, P.; Mao, X.; Engelstad, K.M.; Hinton, V.; DiMauro, S.; De Vivo, D.; Shungu, D. Cerebral metabolic abnormalities in a3243g mitochondrial DNA mutation carriers. Neurology 2014, 82, 798–805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taylor, R.W.; Turnbull, D.M. Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 2005, 6, 389–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Finsterer, J. Mitochondrial metabolic stroke: Phenotype and genetics of stroke-like episodes. J. Neurol. Sci. 2019, 400, 135–141. [Google Scholar] [CrossRef]
- Finsterer, J.; Aliyev, R. Metabolic stroke or stroke-like lesion: Peculiarities of a phenomenon. J. Neurol. Sci. 2020, 412, 116726. [Google Scholar] [CrossRef]
- Smeitink, J.; Koene, S.; Beyrath, J.; Saris, C.; Turnbull, D.; Janssen, M. Mitochondrial migraine: Disentangling the angiopathy paradigm in m.3243a>g patients. JIMD Rep. 2019, 46, 52–62. [Google Scholar]
- Betts, J.; Jaros, E.; Perry, R.H.; Schaefer, A.M.; Taylor, R.W.; Abdel-All, Z.; Lightowlers, R.N.; Turnbull, D.M. Molecular neuropathology of melas: Level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol. Appl. Neurobiol. 2006, 32, 359–373. [Google Scholar] [CrossRef]
- Yoshida, T.; Ouchi, A.; Miura, D.; Shimoji, K.; Kinjo, K.; Sueyoshi, T.; Jonosono, M.; Rajput, V. Melas and reversible vasoconstriction of the major cerebral arteries. Intern. Med. 2013, 52, 1389–1392. [Google Scholar] [CrossRef] [Green Version]
- Hayashi, G.; Cortopassi, G. Oxidative stress in inherited mitochondrial diseases. Free Radic. Biol. Med. 2015, 88, 10–17. [Google Scholar] [CrossRef] [Green Version]
- Janssen, G.M.; Hensbergen, P.J.; van Bussel, F.J.; Balog, C.I.; Maassen, J.A.; Deelder, A.M.; Raap, A.K. The a3243g trnaleu(uur) mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex iv subunits at uur codons. Hum. Mol. Genet. 2007, 16, 2472–2481. [Google Scholar] [CrossRef] [Green Version]
- Yang, H.; Brosel, S.; Acin-Perez, R.; Slavkovich, V.; Nishino, I.; Khan, R.; Goldberg, I.J.; Graziano, J.; Manfredi, G.; Schon, E.A. Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in sco2. Hum. Mol. Genet. 2010, 19, 170–180. [Google Scholar] [CrossRef] [Green Version]
- Ciafaloni, E.; Ricci, E.; Servidei, S.; Shanske, S.; Silvestri, G.; Manfredi, G.; Schon, E.A.; DiMauro, S. Widespread tissue distribution of a trnaleu(uur) mutation in the mitochondrial DNA of a patient with melas syndrome. Neurology 1991, 41, 1663–1664. [Google Scholar] [CrossRef]
- Muller-Hocker, J.; Hubner, G.; Bise, K.; Forster, C.; Hauck, S.; Paetzke, I.; Pongratz, D.; Kadenbach, B. Generalized mitochondrial microangiopathy and vascular cytochrome c oxidase deficiency. Occurrence in a case of melas syndrome with mitochondrial cardiomyopathy-myopathy and combined complex i/iv deficiency. Arch. Pathol. Lab. Med. 1993, 117, 202–210. [Google Scholar] [PubMed]
- Tengan, C.H.; Kiyomoto, B.H.; Godinho, R.O.; Gamba, J.; Neves, A.C.; Schmidt, B.; Oliveira, A.S.; Gabbai, A.A. The role of nitric oxide in muscle fibers with oxidative phosphorylation defects. Biochem. Biophys. Res. Commun. 2007, 359, 771–777. [Google Scholar] [CrossRef] [PubMed]
- Mattila, J.T.; Thomas, A.C. Nitric oxide synthase: Non-canonical expression patterns. Front. Immunol. 2014, 5, 478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buerk, D.G. Nitric oxide regulation of microvascular oxygen. Antioxid. Redox Signal. 2007, 9, 829–843. [Google Scholar] [CrossRef]
- Green, D.J.; Dawson, E.A.; Groenewoud, H.M.; Jones, H.; Thijssen, D.H. Is flow-mediated dilation nitric oxide mediated? A meta-analysis. Hypertension 2014, 63, 376–382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vattemi, G.; Mechref, Y.; Marini, M.; Tonin, P.; Minuz, P.; Grigoli, L.; Guglielmi, V.; Klouckova, I.; Chiamulera, C.; Meneguzzi, A.; et al. Increased protein nitration in mitochondrial diseases: Evidence for vessel wall involvement. Mol. Cell Proteom. 2011, 10, M110.002964. [Google Scholar] [CrossRef] [Green Version]
- El-Hattab, A.W.; Emrick, L.T.; Craigen, W.J.; Scaglia, F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol. Genet. Metab. 2012, 107, 247–252. [Google Scholar] [CrossRef]
- Naini, A.; Kaufmann, P.; Shanske, S.; Engelstad, K.; De Vivo, D.C.; Schon, E.A. Hypocitrullinemia in patients with melas: An insight into the “melas paradox”. J. Neurol. Sci. 2005, 229–230, 187–193. [Google Scholar] [CrossRef]
- Bottani, E.; Lamperti, C.; Prigione, A.; Tiranti, V.; Persico, N.; Brunetti, D. Therapeutic approaches to treat mitochondrial diseases: “One-size-fits-all” and “precision medicine” strategies. Pharmaceutics 2020, 12, 1083. [Google Scholar] [CrossRef]
- Haines, R.J.; Pendleton, L.C.; Eichler, D.C. Argininosuccinate synthase: At the center of arginine metabolism. Int. J. Biochem. Mol. Biol. 2011, 2, 8–23. [Google Scholar]
- Pavlakis, S.G.; Phillips, P.C.; DiMauro, S.; De Vivo, D.C.; Rowland, L.P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome. Ann. Neurol. 1984, 16, 481–488. [Google Scholar] [CrossRef]
- Orsucci, D.; Caldarazzo Ienco, E.; Rossi, A.; Siciliano, G.; Mancuso, M. Mitochondrial syndromes revisited. J. Clin. Med. 2021, 10, 1249. [Google Scholar] [CrossRef]
- Pia, S.; Lui, F. Melas Syndrome; Statpearls: Treasure Island, FL, USA, 2021. [Google Scholar]
- Vincent, A.E.; Ng, Y.S.; White, K.; Davey, T.; Mannella, C.; Falkous, G.; Feeney, C.; Schaefer, A.M.; McFarland, R.; Gorman, G.S.; et al. The spectrum of mitochondrial ultrastructural defects in mitochondrial myopathy. Sci. Rep. 2016, 6, 30610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirano, M.; Ricci, E.; Koenigsberger, M.R.; Defendini, R.; Pavlakis, S.G.; DeVivo, D.C.; DiMauro, S.; Rowland, L.P. Melas: An original case and clinical criteria for diagnosis. Neuromuscul. Disord. 1992, 2, 125–135. [Google Scholar] [CrossRef]
- Lorenzoni, P.J.; Werneck, L.C.; Kay, C.S.; Silvado, C.E.; Scola, R.H. When should melas (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) be the diagnosis? Arq. Neuropsiquiatr. 2015, 73, 959–967. [Google Scholar] [CrossRef] [PubMed]
- de Laat, P.; Koene, S.; van den Heuvel, L.P.; Rodenburg, R.J.; Janssen, M.C.; Smeitink, J.A. Clinical features and heteroplasmy in blood, urine and saliva in 34 dutch families carrying the m.3243a > g mutation. J. Inherit. Metab. Dis. 2012, 35, 1059–1069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marotta, R.; Reardon, K.; McKelvie, P.A.; Chiotis, M.; Chin, J.; Cook, M.; Collins, S.J. Association of the melas m.3243a>g mutation with myositis and the superiority of urine over muscle, blood and hair for mutation detection. J. Clin. Neurosci. 2009, 16, 1223–1225. [Google Scholar] [CrossRef] [PubMed]
- Rahman, S.; Poulton, J.; Marchington, D.; Suomalainen, A. Decrease of 3243 a-->g mtdna mutation from blood in melas syndrome: A longitudinal study. Am. J. Hum. Genet. 2001, 68, 238–240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chinnery, P.F.; Howell, N.; Lightowlers, R.N.; Turnbull, D.M. Melas and merrf. The relationship between maternal mutation load and the frequency of clinically affected offspring. Brain 1998, 121 Pt 10, 1889–1894. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chinnery, P.F.; Howell, N.; Lightowlers, R.N.; Turnbull, D.M. Molecular pathology of melas and merrf. The relationship between mutation load and clinical phenotypes. Brain 1997, 120 Pt 10, 1713–1721. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McDonnell, M.T.; Schaefer, A.M.; Blakely, E.L.; McFarland, R.; Chinnery, P.F.; Turnbull, D.M.; Taylor, R.W. Noninvasive diagnosis of the 3243a > g mitochondrial DNA mutation using urinary epithelial cells. Eur. J. Hum. Genet. 2004, 12, 778–781. [Google Scholar] [CrossRef] [PubMed]
- Fayssoil, A.; Laforet, P.; Bougouin, W.; Jardel, C.; Lombes, A.; Becane, H.M.; Berber, N.; Stojkovic, T.; Behin, A.; Eymard, B.; et al. Prediction of long-term prognosis by heteroplasmy levels of the m.3243a>g mutation in patients with the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome. Eur. J. Neurol. 2017, 24, 255–261. [Google Scholar] [CrossRef] [PubMed]
- Whittaker, R.G.; Blackwood, J.K.; Alston, C.L.; Blakely, E.L.; Elson, J.L.; McFarland, R.; Chinnery, P.F.; Turnbull, D.M.; Taylor, R.W. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243a>g mtdna mutation. Neurology 2009, 72, 568–569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shanske, S.; Pancrudo, J.; Kaufmann, P.; Engelstad, K.; Jhung, S.; Lu, J.; Naini, A.; DiMauro, S.; De Vivo, D.C. Varying loads of the mitochondrial DNA a3243g mutation in different tissues: Implications for diagnosis. Am. J. Med. Genet. A 2004, 130, 134–137. [Google Scholar] [CrossRef] [PubMed]
- Dindyal, S.; Mistry, K.; Angamuthu, N.; Smith, G.; Hilton, D.; Arumugam, P.; Mathew, J. Melas syndrome presenting as an acute surgical abdomen. Ann. R Coll. Surg. Engl. 2014, 96, 101E–103E. [Google Scholar] [CrossRef]
- Kaufmann, P.; Shungu, D.C.; Sano, M.C.; Jhung, S.; Engelstad, K.; Mitsis, E.; Mao, X.; Shanske, S.; Hirano, M.; DiMauro, S.; et al. Cerebral lactic acidosis correlates with neurological impairment in melas. Neurology 2004, 62, 1297–1302. [Google Scholar] [CrossRef] [Green Version]
- Laloi-Michelin, M.; Meas, T.; Ambonville, C.; Bellanne-Chantelot, C.; Beaufils, S.; Massin, P.; Vialettes, B.; Gin, H.; Timsit, J.; Bauduceau, B.; et al. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. J. Clin. Endocrinol. Metab. 2009, 94, 3025–3030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Macmillan, C.; Lach, B.; Shoubridge, E.A. Variable distribution of mutant mitochondrial dnas (trna(leu [3243])) in tissues of symptomatic relatives with melas: The role of mitotic segregation. Neurology 1993, 43, 1586–1590. [Google Scholar] [CrossRef]
- Sato, W.; Hayasaka, K.; Komatsu, K.; Sawaishi, Y.; Sakemi, K.; Shoji, Y.; Takada, G. Genetic analysis of three pedigrees of mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (melas). Am. J. Hum. Genet. 1992, 50, 655–657. [Google Scholar]
- Pickett, S.J.; Grady, J.P.; Ng, Y.S.; Gorman, G.S.; Schaefer, A.M.; Wilson, I.J.; Cordell, H.J.; Turnbull, D.M.; Taylor, R.W.; McFarland, R. Phenotypic heterogeneity in m.3243a>g mitochondrial disease: The role of nuclear factors. Ann. Clin. Transl. Neurol. 2018, 5, 333–345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seo, G.H.; Oh, A.; Kim, E.N.; Lee, Y.; Park, J.; Kim, T.; Lim, Y.M.; Kim, G.H.; Kim, C.J.; Yoo, H.W.; et al. Identification of extremely rare mitochondrial disorders by whole exome sequencing. J. Hum. Genet. 2019, 64, 1117–1125. [Google Scholar] [CrossRef]
- Calvo, S.E.; Compton, A.G.; Hershman, S.G.; Lim, S.C.; Lieber, D.S.; Tucker, E.J.; Laskowski, A.; Garone, C.; Liu, S.; Jaffe, D.B.; et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci. Transl. Med. 2012, 4, 118ra110. [Google Scholar] [CrossRef] [Green Version]
- Baek, M.S.; Kim, S.H.; Lee, Y.M. The usefulness of muscle biopsy in initial diagnostic evaluation of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Yonsei Med. J. 2019, 60, 98–105. [Google Scholar] [CrossRef]
- Craven, L.; Tang, M.X.; Gorman, G.S.; De Sutter, P.; Heindryckx, B. Novel reproductive technologies to prevent mitochondrial disease. Hum. Reprod. Update 2017, 23, 501–519. [Google Scholar] [CrossRef] [Green Version]
- Sallevelt, S.; Dreesen, J.; Coonen, E.; Paulussen, A.D.C.; Hellebrekers, D.; de Die-Smulders, C.E.M.; Smeets, H.J.M.; Lindsey, P. Preimplantation genetic diagnosis for mitochondrial DNA mutations: Analysis of one blastomere suffices. J. Med. Genet. 2017, 54, 693–697. [Google Scholar] [CrossRef]
- Treff, N.R.; Campos, J.; Tao, X.; Levy, B.; Ferry, K.M.; Scott, R.T., Jr. Blastocyst preimplantation genetic diagnosis (pgd) of a mitochondrial DNA disorder. Fertil. Steril. 2012, 98, 1236–1240. [Google Scholar] [CrossRef]
- Craven, L.; Tuppen, H.A.; Greggains, G.D.; Harbottle, S.J.; Murphy, J.L.; Cree, L.M.; Murdoch, A.P.; Chinnery, P.F.; Taylor, R.W.; Lightowlers, R.N.; et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010, 465, 82–85. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dean, N.L.; Battersby, B.J.; Ao, A.; Gosden, R.G.; Tan, S.L.; Shoubridge, E.A.; Molnar, M.J. Prospect of preimplantation genetic diagnosis for heritable mitochondrial DNA diseases. Mol. Hum. Reprod. 2003, 9, 631–638. [Google Scholar] [CrossRef] [PubMed]
- Rossignol, R.; Faustin, B.; Rocher, C.; Malgat, M.; Mazat, J.P.; Letellier, T. Mitochondrial threshold effects. Biochem. J. 2003, 370, 751–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rahman, S. Mitochondrial disease and epilepsy. Dev. Med. Child. Neurol. 2012, 54, 397–406. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Demarest, S.T.; Whitehead, M.T.; Turnacioglu, S.; Pearl, P.L.; Gropman, A.L. Phenotypic analysis of epilepsy in the mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes-associated mitochondrial DNA a3243g mutation. J. Child. Neurol. 2014, 29, 1249–1256. [Google Scholar] [CrossRef] [PubMed]
- Iizuka, T.; Sakai, F.; Suzuki, N.; Hata, T.; Tsukahara, S.; Fukuda, M.; Takiyama, Y. Neuronal hyperexcitability in stroke-like episodes of melas syndrome. Neurology 2002, 59, 816–824. [Google Scholar] [CrossRef] [PubMed]
- Fryer, R.H.; Bain, J.M.; De Vivo, D.C. Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (melas): A case report and critical reappraisal of treatment options. Pediatr. Neurol. 2016, 56, 59–61. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.F.; Chi, C.S.; Tsai, C.R.; Chen, C.H. Epileptic seizures in infants and children with mitochondrial diseases. Pediatr. Neurol. 2011, 45, 169–174. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.M.; Kang, H.C.; Lee, J.S.; Kim, S.H.; Kim, E.Y.; Lee, S.K.; Slama, A.; Kim, H.D. Mitochondrial respiratory chain defects: Underlying etiology in various epileptic conditions. Epilepsia 2008, 49, 685–690. [Google Scholar] [CrossRef]
- DeFronzo, R.; Fleming, G.A.; Chen, K.; Bicsak, T.A. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism 2016, 65, 20–29. [Google Scholar] [CrossRef] [Green Version]
- Maeda, K.; Tatsumi, M.; Tahara, M.; Murata, Y.; Kawai, H.; Yasuda, H. A case of stroke-like episode of melas of which progressive spread would be prevented by edaravone. Rinsho Shinkeigaku 2005, 45, 416–421. [Google Scholar]
- Walcott, B.P.; Edlow, B.L.; Xia, Z.; Kahle, K.T.; Nahed, B.V.; Schmahmann, J.D. Steroid responsive a3243g mutation melas: Clinical and radiographic evidence for regional hyperperfusion leading to neuronal loss. Neurologist 2012, 18, 159–170. [Google Scholar] [CrossRef] [PubMed]
- Bindu, P.S.; Sonam, K.; Chiplunkar, S.; Govindaraj, P.; Nagappa, M.; Vekhande, C.C.; Aravinda, H.R.; Ponmalar, J.J.; Mahadevan, A.; Gayathri, N.; et al. Mitochondrial leukoencephalopathies: A border zone between acquired and inherited white matter disorders in children? Mult. Scler. Relat. Disord. 2018, 20, 84–92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hue, C.D.; Cho, F.S.; Cao, S.; Dale Bass, C.R.; Meaney, D.F.; Morrison, B., 3rd. Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of zo-1 tight junction protein. J. Cereb. Blood Flow Metab. 2015, 35, 1191–1198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Finsterer, J. Commentary: Neuromuscular and muscle metabolic functions in melas before and after resistance training: A case study. Front. Physiol. 2019, 10, 1178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Venturelli, M.; Villa, F.; Ruzzante, F.; Tarperi, C.; Rudi, D.; Milanese, C.; Cavedon, V.; Fonte, C.; Picelli, A.; Smania, N.; et al. Neuromuscular and muscle metabolic functions in melas before and after resistance training: A case study. Front. Physiol. 2019, 10, 503. [Google Scholar] [CrossRef] [Green Version]
- Hayden, E.C. Regulators weigh benefits of ‘three-parent’ fertilization. Nature 2013, 502, 284–285. [Google Scholar] [CrossRef]
- Barcelos, I.; Shadiack, E.; Ganetzky, R.D.; Falk, M.J. Mitochondrial medicine therapies: Rationale, evidence, and dosing guidelines. Curr. Opin. Pediatr. 2020, 32, 707–718. [Google Scholar] [CrossRef]
- Chauhan, A.; Srivastva, N.; Bubber, P. Thiamine deficiency induced dietary disparity promotes oxidative stress and neurodegeneration. Indian J. Clin. Biochem. 2018, 33, 422–428. [Google Scholar] [CrossRef]
- Depeint, F.; Bruce, W.R.; Shangari, N.; Mehta, R.; O’Brien, P.J. Mitochondrial function and toxicity: Role of the b vitamin family on mitochondrial energy metabolism. Chem. Biol. Interact. 2006, 163, 94–112. [Google Scholar] [CrossRef]
- Mosegaard, S.; Dipace, G.; Bross, P.; Carlsen, J.; Gregersen, N.; Olsen, R.K.J. Riboflavin deficiency-implications for general human health and inborn errors of metabolism. Int. J. Mol. Sci. 2020, 21, 3847. [Google Scholar] [CrossRef]
- Auclair, O.; Han, Y.; Burgos, S.A. Consumption of milk and alternatives and their contribution to nutrient intakes among canadian adults: Evidence from the 2015 canadian community health survey-nutrition. Nutrients 2019, 11, 1948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Penn, A.M.; Lee, J.W.; Thuillier, P.; Wagner, M.; Maclure, K.M.; Menard, M.R.; Hall, L.D.; Kennaway, N.G. Melas syndrome with mitochondrial trna(leu)(uur) mutation: Correlation of clinical state, nerve conduction, and muscle 31p magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992, 42, 2147–2152. [Google Scholar] [CrossRef] [PubMed]
- Garrido-Maraver, J.; Cordero, M.D.; Monino, I.D.; Pereira-Arenas, S.; Lechuga-Vieco, A.V.; Cotan, D.; De la Mata, M.; Oropesa-Avila, M.; De Miguel, M.; Bautista Lorite, J.; et al. Screening of effective pharmacological treatments for melas syndrome using yeasts, fibroblasts and cybrid models of the disease. Br. J. Pharmacol. 2012, 167, 1311–1328. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.; Tsukikawa, M.; Peng, M.; Polyak, E.; Nakamaru-Ogiso, E.; Ostrovsky, J.; McCormack, S.; Place, E.; Clarke, C.; Reiner, G.; et al. Primary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling network. PLoS ONE 2013, 8, e69282. [Google Scholar] [CrossRef]
- McCormack, S.; Polyak, E.; Ostrovsky, J.; Dingley, S.D.; Rao, M.; Kwon, Y.J.; Xiao, R.; Zhang, Z.; Nakamaru-Ogiso, E.; Falk, M.J. Pharmacologic targeting of sirtuin and ppar signaling improves longevity and mitochondrial physiology in respiratory chain complex i mutant caenorhabditis elegans. Mitochondrion 2015, 22, 45–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zempleni, J.; Hassan, Y.I.; Wijeratne, S.S. Biotin and biotinidase deficiency. Expert Rev. Endocrinol. Metab. 2008, 3, 715–724. [Google Scholar] [CrossRef] [Green Version]
- Marriage, B.J.; Clandinin, M.T.; Macdonald, I.M.; Glerum, D.M. Cofactor treatment improves atp synthetic capacity in patients with oxidative phosphorylation disorders. Mol. Genet. Metab. 2004, 81, 263–272. [Google Scholar] [CrossRef]
- Pietrzik, K.; Bailey, L.; Shane, B. Folic acid and l-5-methyltetrahydrofolate: Comparison of clinical pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2010, 49, 535–548. [Google Scholar] [CrossRef]
- Ormazabal, A.; Casado, M.; Molero-Luis, M.; Montoya, J.; Rahman, S.; Aylett, S.B.; Hargreaves, I.; Heales, S.; Artuch, R. Can folic acid have a role in mitochondrial disorders? Drug. Discov. Today 2015, 20, 1349–1354. [Google Scholar] [CrossRef]
- Scaglione, F.; Panzavolta, G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica 2014, 44, 480–488. [Google Scholar] [CrossRef]
- Knowles, L.; Morris, A.A.; Walter, J.H. Treatment with mefolinate (5-methyltetrahydrofolate), but not folic acid or folinic acid, leads to measurable 5-methyltetrahydrofolate in cerebrospinal fluid in methylenetetrahydrofolate reductase deficiency. JIMD Rep. 2016, 29, 103–107. [Google Scholar] [PubMed] [Green Version]
- Kronenberg, G.; Gertz, K.; Overall, R.W.; Harms, C.; Klein, J.; Page, M.M.; Stuart, J.A.; Endres, M. Folate deficiency increases mtdna and d-1 mtdna deletion in aged brain of mice lacking uracil-DNA glycosylase. Exp. Neurol. 2011, 228, 253–258. [Google Scholar] [CrossRef] [PubMed]
- Sunde, K.; Blackburn, P.R.; Cheema, A.; Gass, J.; Jackson, J.; Macklin, S.; Atwal, P.S. Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (melas). Mol. Genet. Metab. Rep. 2016, 9, 94–97. [Google Scholar] [CrossRef] [PubMed]
- Froese, D.S.; Fowler, B.; Baumgartner, M.R. Vitamin b12, folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation. J. Inherit. Metab. Dis. 2019, 42, 673–685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palmer, A.M.; Kamynina, E.; Field, M.S.; Stover, P.J. Folate rescues vitamin b12 depletion-induced inhibition of nuclear thymidylate biosynthesis and genome instability. Proc. Natl. Acad. Sci. USA 2017, 114, E4095–E4102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Green, R.; Allen, L.H.; Bjorke-Monsen, A.L.; Brito, A.; Gueant, J.L.; Miller, J.W.; Molloy, A.M.; Nexo, E.; Stabler, S.; Toh, B.H.; et al. Vitamin b12 deficiency. Nat. Rev. Dis. Primers 2017, 3, 17040. [Google Scholar] [CrossRef]
- Napolitano, G.; Fasciolo, G.; Di Meo, S.; Venditti, P. Vitamin e supplementation and mitochondria in experimental and functional hyperthyroidism: A mini-review. Nutrients 2019, 11, 2900. [Google Scholar] [CrossRef] [Green Version]
- Polyak, E.; Ostrovsky, J.; Peng, M.; Dingley, S.D.; Tsukikawa, M.; Kwon, Y.J.; McCormack, S.E.; Bennett, M.; Xiao, R.; Seiler, C.; et al. N-acetylcysteine and vitamin e rescue animal longevity and cellular oxidative stress in pre-clinical models of mitochondrial complex i disease. Mol. Genet. Metab. 2018, 123, 449–462. [Google Scholar] [CrossRef]
- Quinzii, C.M.; Lopez, L.C.; Von-Moltke, J.; Naini, A.; Krishna, S.; Schuelke, M.; Salviati, L.; Navas, P.; DiMauro, S.; Hirano, M. Respiratory chain dysfunction and oxidative stress correlate with severity of primary coq10 deficiency. FASEB J. 2008, 22, 1874–1885. [Google Scholar] [CrossRef] [Green Version]
- Gold, D.R.; Cohen, B.H. Treatment of mitochondrial cytopathies. Semin. Neurol. 2001, 21, 309–325. [Google Scholar] [CrossRef] [Green Version]
- Kerr, D.S. Treatment of mitochondrial electron transport chain disorders: A review of clinical trials over the past decade. Mol. Genet. Metab. 2010, 99, 246–255. [Google Scholar] [CrossRef]
- Haas, R.H. The evidence basis for coenzyme q therapy in oxidative phosphorylation disease. Mitochondrion 2007, 7 (Suppl. 1), S136–S145. [Google Scholar] [CrossRef]
- Zozina, V.I.; Covantev, S.; Goroshko, O.A.; Krasnykh, L.M.; Kukes, V.G. Coenzyme q10 in cardiovascular and metabolic diseases: Current state of the problem. Curr. Cardiol. Rev. 2018, 14, 164–174. [Google Scholar] [CrossRef]
- Fernandez-Vega, B.; Gonzalez-Iglesias, H.; Vega, J.A.; Nicieza, J.; Fernandez-Vega, A. Coenzyme q10 treatment improved visual field after homonymous quadrantanopia caused by occipital lobe infarction. Am. J. Ophthalmol. Case Rep. 2019, 13, 70–75. [Google Scholar] [CrossRef]
- Lalani, S.R.; Vladutiu, G.D.; Plunkett, K.; Lotze, T.E.; Adesina, A.M.; Scaglia, F. Isolated mitochondrial myopathy associated with muscle coenzyme q10 deficiency. Arch. Neurol. 2005, 62, 317–320. [Google Scholar] [CrossRef] [Green Version]
- Mancuso, M.; Orsucci, D.; Calsolaro, V.; Choub, A.; Siciliano, G. Coenzyme q10 and neurological diseases. Pharmaceuticals 2009, 2, 134–149. [Google Scholar] [CrossRef]
- Glover, E.I.; Martin, J.; Maher, A.; Thornhill, R.E.; Moran, G.R.; Tarnopolsky, M.A. A randomized trial of coenzyme q10 in mitochondrial disorders. Muscle Nerve 2010, 42, 739–748. [Google Scholar] [CrossRef]
- Cotan, D.; Cordero, M.D.; Garrido-Maraver, J.; Oropesa-Avila, M.; Rodriguez-Hernandez, A.; Gomez Izquierdo, L.; De la Mata, M.; De Miguel, M.; Lorite, J.B.; Infante, E.R.; et al. Secondary coenzyme q10 deficiency triggers mitochondria degradation by mitophagy in melas fibroblasts. FASEB J. 2011, 25, 2669–2687. [Google Scholar] [CrossRef]
- Hirano, M.; Emmanuele, V.; Quinzii, C.M. Emerging therapies for mitochondrial diseases. Essays Biochem 2018, 62, 467–481. [Google Scholar]
- Atkuri, K.R.; Mantovani, J.J.; Herzenberg, L.A.; Herzenberg, L.A. N-acetylcysteine—A safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 2007, 7, 355–359. [Google Scholar] [CrossRef] [Green Version]
- Moss, H.G.; Brown, T.R.; Wiest, D.B.; Jenkins, D.D. N-acetylcysteine rapidly replenishes central nervous system glutathione measured via magnetic resonance spectroscopy in human neonates with hypoxic-ischemic encephalopathy. J. Cereb. Blood Flow Metab. 2018, 38, 950–958. [Google Scholar] [CrossRef]
- Scaglia, F.; Northrop, J.L. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (melas) syndrome: A review of treatment options. CNS Drugs 2006, 20, 443–464. [Google Scholar] [CrossRef]
- Granger, M.; Eck, P. Dietary vitamin c in human health. Adv. Food Nutr. Res. 2018, 83, 281–310. [Google Scholar]
- Ha, M.N.; Graham, F.L.; D’Souza, C.K.; Muller, W.J.; Igdoura, S.A.; Schellhorn, H.E. Functional rescue of vitamin c synthesis deficiency in human cells using adenoviral-based expression of murine l-gulono-gamma-lactone oxidase. Genomics 2004, 83, 482–492. [Google Scholar] [CrossRef]
- Naidu, K.A. Vitamin c in human health and disease is still a mystery? An overview. Nutr. J. 2003, 2, 7. [Google Scholar] [CrossRef] [Green Version]
- Rivas, C.I.; Zuniga, F.A.; Salas-Burgos, A.; Mardones, L.; Ormazabal, V.; Vera, J.C. Vitamin c transporters. J. Physiol. Biochem. 2008, 64, 357–375. [Google Scholar] [CrossRef]
- Kc, S.; Carcamo, J.M.; Golde, D.W. Vitamin c enters mitochondria via facilitative glucose transporter 1 (glut1) and confers mitochondrial protection against oxidative injury. FASEB J. 2005, 19, 1657–1667. [Google Scholar] [CrossRef]
- Marriage, B.; Clandinin, M.T.; Glerum, D.M. Nutritional cofactor treatment in mitochondrial disorders. J. Am. Diet. Assoc. 2003, 103, 1029–1038. [Google Scholar] [CrossRef]
- Enns, G.M.; Bennett, M.J.; Hoppel, C.L.; Goodman, S.I.; Weisiger, K.; Ohnstad, C.; Golabi, M.; Packman, S. Mitochondrial respiratory chain complex i deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme a dehydrogenase deficiency. J. Pediatr 2000, 136, 251–254. [Google Scholar] [CrossRef]
- Santidrian, A.F.; Matsuno-Yagi, A.; Ritland, M.; Seo, B.B.; LeBoeuf, S.E.; Gay, L.J.; Yagi, T.; Felding-Habermann, B. Mitochondrial complex i activity and nad+/nadh balance regulate breast cancer progression. J. Clin. Investig. 2013, 123, 1068–1081. [Google Scholar] [CrossRef] [Green Version]
- Parikh, S.; Saneto, R.; Falk, M.J.; Anselm, I.; Cohen, B.H.; Haas, R.; Medicine Society, T.M. A modern approach to the treatment of mitochondrial disease. Curr. Treat. Options Neurol. 2009, 11, 414–430. [Google Scholar] [CrossRef] [Green Version]
- Tarnopolsky, M.A. The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv. Drug Deliv. Rev. 2008, 60, 1561–1567. [Google Scholar] [CrossRef]
- Santa, K.M. Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (melas) syndrome. Pharmacotherapy 2010, 30, 1179–1196. [Google Scholar] [CrossRef]
- Rodriguez, M.C.; MacDonald, J.R.; Mahoney, D.J.; Parise, G.; Beal, M.F.; Tarnopolsky, M.A. Beneficial effects of creatine, coq10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35, 235–242. [Google Scholar] [CrossRef]
- Kornblum, C.; Schroder, R.; Muller, K.; Vorgerd, M.; Eggers, J.; Bogdanow, M.; Papassotiropoulos, A.; Fabian, K.; Klockgether, T.; Zange, J. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: A placebo-controlled, double-blind 31p-mrs crossover study. Eur. J. Neurol. 2005, 12, 300–309. [Google Scholar] [CrossRef]
- Cavero, T.; Rabasco, C.; Molero, A.; Blazquez, A.; Hernandez, E.; Martin, M.A.; Praga, M. When should a nephrologist suspect a mitochondrial disease? Nefrologia 2015, 35, 6–17. [Google Scholar]
- Koga, Y.; Akita, Y.; Junko, N.; Yatsuga, S.; Povalko, N.; Fukiyama, R.; Ishii, M.; Matsuishi, T. Endothelial dysfunction in melas improved by l-arginine supplementation. Neurology 2006, 66, 1766–1769. [Google Scholar] [CrossRef]
- Ganetzky, R.D.; Falk, M.J. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol. Genet. Metab. 2018, 123, 301–308. [Google Scholar] [CrossRef]
- Ikawa, M.; Povalko, N.; Koga, Y. Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Curr. Opin. Clin. Nutr. Metab. Care 2020, 23, 17–22. [Google Scholar] [CrossRef]
- El-Hattab, A.W.; Emrick, L.T.; Williamson, K.C.; Craigen, W.J.; Scaglia, F. The effect of citrulline and arginine supplementation on lactic acidemia in melas syndrome. Meta Gene 2013, 1, 8–14. [Google Scholar] [CrossRef]
- Koga, Y.; Povalko, N.; Inoue, E.; Nakamura, H.; Ishii, A.; Suzuki, Y.; Yoneda, M.; Kanda, F.; Kubota, M.; Okada, H.; et al. Therapeutic regimen of l-arginine for melas: 9-year, prospective, multicenter, clinical research. J. Neurol. 2018, 265, 2861–2874. [Google Scholar] [CrossRef] [Green Version]
- Finsterer, J. Whether no-precursors are truly beneficial for stroke-like episodes remains unsolved. J. Neurol. 2019, 266, 245–246. [Google Scholar] [CrossRef]
- Cade, W.T.; Reeds, D.N.; Peterson, L.R.; Bohnert, K.L.; Tinius, R.A.; Benni, P.B.; Byrne, B.J.; Taylor, C.L. Endurance exercise training in young adults with barth syndrome: A pilot study. JIMD Rep. 2017, 32, 15–24. [Google Scholar]
- Cejudo, P.; Bautista, J.; Montemayor, T.; Villagomez, R.; Jimenez, L.; Ortega, F.; Campos, Y.; Sanchez, H.; Arenas, J. Exercise training in mitochondrial myopathy: A randomized controlled trial. Muscle Nerve 2005, 32, 342–350. [Google Scholar] [CrossRef]
- Jeppesen, T.D.; Schwartz, M.; Olsen, D.B.; Wibrand, F.; Krag, T.; Duno, M.; Hauerslev, S.; Vissing, J. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006, 129, 3402–3412. [Google Scholar] [CrossRef] [Green Version]
- Pesta, D.; Hoppel, F.; Macek, C.; Messner, H.; Faulhaber, M.; Kobel, C.; Parson, W.; Burtscher, M.; Schocke, M.; Gnaiger, E. Similar qualitative and quantitative changes of mitochondrial respiration following strength and endurance training in normoxia and hypoxia in sedentary humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301, R1078–R1087. [Google Scholar] [CrossRef] [Green Version]
- Taivassalo, T.; Gardner, J.L.; Taylor, R.W.; Schaefer, A.M.; Newman, J.; Barron, M.J.; Haller, R.G.; Turnbull, D.M. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtdna deletions. Brain 2006, 129, 3391–3401. [Google Scholar] [CrossRef] [Green Version]
- Taivassalo, T.; Shoubridge, E.A.; Chen, J.; Kennaway, N.G.; DiMauro, S.; Arnold, D.L.; Haller, R.G. Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects. Ann. Neurol. 2001, 50, 133–141. [Google Scholar] [CrossRef]
- Adashi, E.Y.; Cohen, I.G. Preventing mitochondrial diseases: Embryo-sparing donor-independent options. Trends Mol. Med. 2018, 24, 449–457. [Google Scholar] [CrossRef]
- Greenfield, A.; Braude, P.; Flinter, F.; Lovell-Badge, R.; Ogilvie, C.; Perry, A.C.F. Assisted reproductive technologies to prevent human mitochondrial disease transmission. Nat. Biotechnol. 2017, 35, 1059–1068. [Google Scholar] [CrossRef] [PubMed]
- Wei, W.; Tuna, S.; Keogh, M.J.; Smith, K.R.; Aitman, T.J.; Beales, P.L.; Bennett, D.L.; Gale, D.P.; Bitner-Glindzicz, M.A.K.; Black, G.C.; et al. Germline selection shapes human mitochondrial DNA diversity. Science 2019, 364, eaau6520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farnezi, H.C.M.; Goulart, A.C.X.; Santos, A.D.; Ramos, M.G.; Penna, M.L.F. Three-parent babies: Mitochondrial replacement therapies. JBRA Assist. Reprod. 2020, 24, 189–196. [Google Scholar] [CrossRef]
- Eyre-Walker, A. Mitochondrial replacement therapy: Are mito-nuclear interactions likely to be a problem? Genetics 2017, 205, 1365–1372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El-Hattab, A.W.; Almannai, M.; Scaglia, F. Melas. In Genereviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fan, H.-C.; Lee, H.-F.; Yue, C.-T.; Chi, C.-S. Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Life 2021, 11, 1111. https://0-doi-org.brum.beds.ac.uk/10.3390/life11111111
Fan H-C, Lee H-F, Yue C-T, Chi C-S. Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Life. 2021; 11(11):1111. https://0-doi-org.brum.beds.ac.uk/10.3390/life11111111
Chicago/Turabian StyleFan, Hueng-Chuen, Hsiu-Fen Lee, Chen-Tang Yue, and Ching-Shiang Chi. 2021. "Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes" Life 11, no. 11: 1111. https://0-doi-org.brum.beds.ac.uk/10.3390/life11111111